Q517--Contingency Chemotherapy Compounding Services for the Louis A. Johnson VA Medical Center

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 seeks contingency hazardous chemotherapy compounding services for the Louis A. Johnson VA Medical Center (LAJVAMC) via a fixed-price five-year IDIQ, with proposals due August 14 at 3:00 PM EDT and questions due August 7. This is an unrestricted acquisition with no set-aside.

Place of performance is 1 Medical Center Drive, Clarksburg, West Virginia 26301. The contractor must provide on-demand aseptic compounding of patient-specific chemotherapy orders, including chemotherapy agents, closed system drug transfer devices, IV tubing, bags, and ancillary supplies, delivered patient-ready prior to scheduled infusion dates. Compounding must occur in an FDA 503A-compliant facility adhering to USP 797 and USP 800 standards. The contractor must maintain a fully validated contingency compounding location meeting all regulatory standards for service disruptions. Orders are submitted via VA secure network or fax with contractor confirmation required within specified timeframes; delivery via courier or overnight mail includes weekend delivery charges in pricing.

The contract ceiling is approximately $349,000 over five years with a minimum guaranteed amount of $300. The base performance period runs August 27, 2026 through August 26, 2027, with four one-year option periods. Billing is based on actual billable units of medication used per patient, with separate line items for compounding labor, drugs, supplies, and shipping. Evaluation uses Lowest Price Technically Acceptable methodology, with award to the lowest evaluated price offeror meeting non-price acceptability standards. The NAICS code is 621610, Medical Laboratories; PSC is Q517, Pharmacy Services. The contracting officer is VA Maryland Health Care System, Perry Point, Maryland, with Sylvia Honesty (Sylvia.Honesty@va.gov) as the point of contact.